Dulaglutide Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: GLP-1 receptor metabolic pharmacology

Metabolic Research peptide Solution verified

Also known as: Trulicity

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes
0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3 mg/0.5 mL, 4.5 mg/0.5 mL
Storage
Refrigerate at 2-8 deg C and protect from light; follow the current label for permitted room-temperature excursions
Solubility
Ready-to-use aqueous injection solution; no reconstitution is required

Catalog Description

Dulaglutide is an FDA-approved GLP-1 receptor agonist marketed as Trulicity for labeled metabolic indications. The product is a ready-to-use subcutaneous solution in single-dose pens and is not a lyophilized research peptide. This catalog entry should describe approved labeling rather than gray-market reconstitution.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life
Approximately 5 days
Onset
Pharmacodynamic glucose effects occur after dosing; stable weekly clinical effects are assessed after repeated administration
Administration Routes (Research)
Subcutaneous (SC)

Reported Research Effects

Reported Research Side Effects

Data source: Current FDA-approved prescribing information

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Route-Specific Research Protocols

Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.

Label / guideline Human study Community only Preclinical only Not established
Subcutaneous (SC) Label / guideline

Weeks 1-4: 0.75 mg once weekly; week 5 onward: 1.5 mg once weekly if additional glycemic control is needed; if further escalation is needed, remain at each dose at least 4 weeks before moving to 3 mg and then 4.5 mg maximum

Frequency / timing
Weekly
Duration / setting
Label-directed chronic use
Technique
SC
Evidence
Regulatory label

Context: current TRULICITY prescribing information

Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.

Route safety: Use only in the cited label or guideline context; route, formulation, indication, and patient-specific limits still apply.

Source 1 Source 2

Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.

Research Interactions

Flagged Avoid / Caution Combinations (Research)

Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.

Research Notes

The prior semaglutide and tirzepatide stack entries were removed because concurrent GLP-1 or dual-incretin agonist use is not an established combination protocol. This is an approved prescription drug record.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

TRULICITY dulaglutide prescribing information — DailyMed (NIH)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af4e38a6-ad3f-480c-ae82-5ac6c7735b99
TRULICITY FDA prescribing information — DailyMed (NIH)
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=af4e38a6-ad3f-480c-ae82-5ac6c7735b99&type=display

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Articles

Published articles on this site that mention Dulaglutide or one of its catalog aliases.

Nisotirostide Obesity Trial: Can NPY2 Add More Weight Loss to GLP-1 Therapy?Read related research article FDA GLP-1 Green List: What Changed in the October 2026 Import AlertRead related research article Vitamin B1 Deficiency and Vision Loss in GLP-1 Users: What the New Evidence ShowsRead related research article FDA GLP-1 Import Alert Targets Adulterated APIsRead related research article

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.

Scroll to Top